Atopic dermatitis (AD) or atopic eczema is a very common skin condition due to skin inflammation. It is usually a long-term condition where the skin becomes itchy, dry, cracked, sore and red. About one in every five children in the UK have AD. This condition may have impacts on the affected child’s quality of life. AD cannot be cured although it can improve significantly, or even clear completely, in some children as they get older. There is an unmet need for safe and effective long-term treatment for moderate-to-severe AD particularly in children.
Dupilumab is a monoclonal antibody medicine that is currently in development as an injection under the skin (subcutaneous) for the treatment of moderate to severe AD in children. Dupilumab is already licensed in the UK for the treatment of moderate-to-severe atopic dermatitis in adults. If licensed, dupilumab will offer an additional treatment option for children aged 12 years to 17 years with moderate to severe atopic dermatitis uncontrolled on current therapies.
Corticosteriods (anti-inflammatory medicines) are usually used for the treatment of PV. Most people will need to take corticosteroids in addition to another medication to help improve the effectiveness and minimise the doses and side effects of corticosteroids. Rituximab is currently being investigated as a treatment option for PV. Rituximab binds specifically to a protein called CD20 located on pre-B and mature B lymphocytes inducing death of these cells. If licensed, rituximab may offer an additional treatment option for patients with PV after failure of systemic steroids and steroid sparing agents to control the disease.